Transcription factor 12 (TCF12) is a known oncogene in many cancers. However, whether TCF12 can regulate malignant phenotypes and angiogenesis in osteosarcoma is not elucidated. In this study, we demonstrated increased expression of TCF12 in osteosarcoma tissues and cell lines. High TCF12 expression was associated with metastasis and poor survival rate of osteosarcoma patients. Knockdown of TCF12 reduced the proliferation, migration, and invasion of osteosarcoma cells. TCF12 was found to bind to the promoter region of sphingosine kinase 1 (SPHK1) to induce transcriptional activation of SPHK1 expression and enhance the secretion of sphingosine-1-phosphate (S1P), which eventually resulted in the malignant phenotypes of osteosarcoma cells. In addition, S1P secreted by osteosarcoma cells promoted the angiogenesis of HUVECs by targeting S1PR4 on the cell membrane to activate the STAT3 signaling pathway. These findings suggest that TCF12 may induce transcriptional activation of SPHK1 to promote the synthesis and secretion of S1P. This process likely enhances the malignant phenotypes of osteosarcoma cells and induces angiogenesis via the S1PR4/STAT3 signaling pathway.
Keyphrases
- induced apoptosis
- signaling pathway
- transcription factor
- cell cycle arrest
- poor prognosis
- gene expression
- endothelial cells
- pi k akt
- endoplasmic reticulum stress
- cell proliferation
- vascular endothelial growth factor
- end stage renal disease
- cell death
- epithelial mesenchymal transition
- chronic kidney disease
- dna methylation
- newly diagnosed
- prognostic factors
- long non coding rna
- wound healing
- young adults
- tyrosine kinase
- patient reported outcomes
- heat stress